The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-18. Anything still debated is marked as such rather than presented as settled.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Other tools include DocFinder at docfinder.docboard.org and certificationmatters.org from the American Board of Medical Specialties. In some cases more information is available from a mailed or walk-in request than the internet; for example, the Medical Board of California removes dismissed accusations from website profiles, but these are still available from a written or walk-in request, or a lookup in a separate database. The trend to disclosure is controversial and generate significant public debate, particularly about opening up the National Practitioner Data Bank. In 1996, Massachusetts became the first state to require detailed disclosure of malpractice claims.
Initiation or Starting module: [F/NMT]-A-PCP- Elongation or Extending modules: -(C/Cy)-[NMT]-A-PCP-[E]- Termination or Releasing module: -(TE/R) (Order: N-terminus to C-terminus; []: optionally; (): alternatively)
==== Traumatic brain injury ==== Atomoxetine is sometimes used in the treatment of cognitive impairment and frontal lobe symptoms due to conditions like traumatic brain injury (TBI). It is used to treat ADHD-like symptoms such as sustained attentional problems, disinhibition, lack of arousal, fatigue, and depression, including symptoms from cognitive disengagement syndrome. A 2015 Cochrane review identified only one study of atomoxetine for TBI and found no positive effects. Aside from TBI, atomoxetine was found to be effective in the treatment of akinetic mutism following subarachnoid hemorrhage in a case report.
== History == The sequence of human GM-CSF was first identified in 1985 and soon three recominbant human GM-CSFs were produced, one in bacteria, one in mammalian cells, and one in yeast; Immunex developed GM-CSF manufactured in yeast into Leukine. Clinical trials of sargramostim were initiated in 1987; in that same year it was administered to six people as part of a compassionate-use protocol for the victims of cesium irradiation from the Goiânia accident. It was approved by the FDA in March 1991, under the brand name Leukine for acceleration of white blood cell recovery following autologous bone marrow transplantation in people with non-Hodgkin's lymphoma, acute lymphocytic leukemia, or Hodgkin's disease. In November 1996, the FDA also approved sargramostim for treatment of fungal infections and replenishment of white blood cells following chemotherapy. A liquid formulation was approved in 1995. Immunex was acquired by Amgen in 2002. As part of the acquisition, Leukine was spun off to Berlex, which became Bayer HealthCare in 2007. In January 2008, Bayer informed healthcare professionals of the market withdrawal of the current liquid formulation of sargramostim. The liquid formulation was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with a change that was made to the formulation around April 2007 to include edetate disodium (EDTA). The upward trend in adverse reaction reporting rates had not been observed with the use of lyophilized sargramostim.
Sources: en.wikipedia.org
=== Military operations === With its built-in stairs and below deck holds, the Il-86 was widely expected to serve in the personnel transport role with the Soviet air forces: "The wide-bodied Il-86 can perform not only as a troop transport ... but may also in the future form the basis for a command and control aircraft for airborne coordination of Warsaw Pact forces." In the event, four airframes (c/n 042, 043, 046 and 048, carrying quasi-civil registrations SSSR-86146, '7, '8 and '9) were delivered to the 8th Special Purposes Aviation Division at the Chkalovsky air base near Moscow. These are variously claimed to be designated Il-80, Il-82, Il-87 or Il-86VKP (Russian: “ВКП” for “воздушный командный пост”; transliterated: "vozdushniy komandnyi post" “veh-kah-peh” and meaning "aerial command post"). This version has the NATO reporting name Maxdome.
== Homogenization == Tissue is typically homogenized in a buffer solution that is isotonic to stop osmotic damage. Mechanisms for homogenization include grinding, mincing, chopping, pressure changes, osmotic shock, freeze-thawing, and ultrasound. The samples are then kept cold to prevent enzymatic damage. It is the formation of homogenous mass of cells (cell homogenate or cell suspension). It involves grinding of cells in a suitable medium in the presence of certain enzymes with correct pH, ionic composition, and temperature. For example, pectinase which digests middle lamella among plant cells.
== Analytical methods == Given the large diversity of PFAS structures that exist, analytical methods for PFAS analysis generally take one of two different approaches: targeted analysis or non-targeted analysis. Targeted methods narrow focus on known PFAS of concern (e.g. PFOA, PFOS) and generally use solid-phase extraction with liquid chromatography–mass spectrometry (LC-MS) detection. For example, EPA Method 537.1 is approved for use in drinking water and can quantify 18 PFAS compounds, while EPA Method 1633A is approved for use for wastewater, surface water, groundwater, soil, biosolids, sediment, landfill leachate, and fish tissue for 40 PFAS chemicals. Regulatory limits for PFOA and PFOS set by the US EPA (4 parts-per-trillion) are limited by the capability of targeted methods to detect low-level concentrations. Non-targeted analyses often sacrifice the identification and quantification of specific PFAS compounds to better understand the amount of PFAS present as a class. For example, total organic fluorine (TOF) analysis quantifies the amount of fluoride produced when a sample is oxidized at high enough temperatures to break the carbon-fluorine bond using combustion ion chromatography. Variants of this analysis include adsorbable organic fluorine (AOF) and extractable organic fluorine (EOF), which use similar solid-phase extraction approaches as the targeted analysis, but use combustion ion chromatography (CIC) as a detector.
=== 20 May === Russia claimed to have taken the village of Bilohorivka, Luhansk Oblast. Two people were killed in Russian attacks in Kherson and Zaporizhzhia Oblast. Ukrainian missiles hit a Russian military facility near Katerynivka, Luhansk Oblast, causing "powerful" explosions and a fire. The Ukrainians claimed to have killed 13 Russian servicemen in the strike, while 26 others were wounded. One of the wounded was allegedly Colonel General Gennadiy Anashkin, commander of Russia's Southern Military District. Deputy Governor of Kharkiv Oblast Roman Semenukha claimed that Ukraine still controls 60% of Vovchansk. A Russian court sentenced 24-year-old Ilya Baburin to 25 years in prison for treason and plotting an arson attack against a recruitment center in Siberia on behalf of Ukraine and setting fire to a local music school.
==== Mass Spectrometry-based Proteomic Methods ==== Conventional shotgun proteomics identification of low abundance proteins in samples remains limited despite advances in Mass Spectrometry (MS) technology. While abundant proteins can be easily detected, possible protease substrates of biological significance, such as cytokines, can be easily overlooked due to their low abundance. Most pre-clearing strategies designed to correct this also risk losing low abundant proteins, thus techniques designed specifically to target protease substrates for identification have been developed. These techniques have coalesced into a new field of positional proteomics or terminomics aimed at identifying protein N- or C-terminal modifications of protease substrates. Terminomic approaches including Terminal Amine Isotopic Labeling of Substrates (TAILS) N-Terminomics, Combined FRActional Diagonal Chromatography (COFRADIC), and C-Terminomics add the level of stringency to conventional shotgun proteomics necessary to make them workhorse of degradomics. TAILS, or “N-Terminomics,” was designed and developed by the Overall Lab to overcome the functional limitations of conventional proteomics by enriching both mature N-terminal peptides and newly generated N-terminal peptides of proteins produced by protease activity. Formaldehyde or isobaric tags including Isotope-coded Affinity Tags (ICAT), 4 to 8 plex Isobaric tag for relative and absolute quantification (iTRAQ), or 10plex Tandem mass tags (TMT) block primary amines prior to trypsin digestion of proteome samples.
Sources: en.wikipedia.org
the vaccination program is not successful in eradicating the disease, on the contrary, it will remain endemic, although at lower levels than the case of absence of vaccinations. This means that the mathematical model suggests that for a disease whose basic reproduction number may be as high as 18 one should vaccinate at least 94.4% of newborns in order to eradicate the disease.
25 December – Gull New Zealand and NPD announce plans to merge their New Zealand operations, subject to approval from the Commerce Commission. 29 December — Gale force winds disrupt camping grounds and festivals, down trees and cause power outages in the upper North Island and Buller District in the South Island's West Coast Region. 30 December — Strong winds cause power disruptions to 10,000 homes and at least 50 cellphone towers in the Tasman District. 31 December – The 2026 New Year Honours are announced.
== Research == Much of the research conducted on demyelinating diseases is targeted towards discovering the mechanisms by which these disorders function in an attempt to develop therapies and treatments for individuals affected by these conditions. For example, proteomics has revealed several proteins which contribute to the pathophysiology of demyelinating diseases. For example, COX-2 has been implicated in oligodendrocyte death in animal models of demyelination. The presence of myelin debris has been correlated with damaging inflammation as well as poor regeneration, due to the presence of inhibitory myelin components. N-cadherin is expressed in regions of active remyelination and may play an important role in generating a local environment conducive to remyelination. N-cadherin agonists have been identified and observed to stimulate neurite growth and cell migration, key aspects of promoting axon growth and remyelination after injury or disease. Immunomodulatory drugs such as fingolimod have been shown to reduce immune-mediated damage to the CNS, preventing further damage in patients with MS. The drug targets the role of macrophages in disease progression. CNS-selective thyromimetics may become a viable strategy to protect myelin and promote remyelination in MS patients. It has been shown that intranasal administration of apotransferrin (aTf) can protect myelin and induce remyelination in mice. Finally, electrical stimulation which activates neural stem cells may provide a method by which regions of demyelination can be repaired.
Cooking with Canned Milk, including recipes and tips Archived 2017-01-29 at the Wayback Machine PET History – history of evaporated milk and the PET company. Today in Science History – John B. Meyenberg's patent describing his evaporation process of preserving milk
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.